National Institute of Health / Mesoblast’s pipeline / /
IndustryTerm
cell bank / alternate site / platform technology / potential solutions / manufacturing practice / healthcare systems / therapies for these intransigent spinal disorders / manufacturing process / histopathology scoring systems / allogeneic cell products / healthcare providers / /
MedicalCondition
inflammatory response / scar / advanced disease / complex disease / bladder dysfunction / ophthalmological diseases / inflammatory and immunological pathways / Subjects With Lumbar Back Pain / intransigent spinal disorders / tissue injury / clinical disease / injury / spinal cord causing inflammation / intractable chronic low back pain / neck and back pain / back pain / orthopedic diseases / persistent chronic low back pain / congestive heart failure / degenerative diseases / host disease / diabetes / FEATURE SPONSOR FEATURE Back pain / pain / diseases / Low back pain / inflammation / CONTENT systemic immunological and inflammatory dysfunction / injuries / disorders / dehydration / /
MedicalTreatment
surgery / surgical treatments / spinal surgery / /
Organization
National Institute of Health / Centre for Devices and Radiological Health / FDA / MPC administration / /
Person
Tony Goldschlager / Freemont / /
Position
Bone Miner / leader / Professor / /
Product
Mesenchymal Precursor Cells Authors Peter Ghosh / MPCs / /
SPONSOR FEATURE SPONSOR FEATURE Back pain—a clinical challenge addressed by Mesoblast using their Mesenchymal